Biodiem Limited

 
 
      

View in Other Languages

News

Australian Market Report of May 25: To Outperform Wall Street

🕔5/25/2009 1:00:32 PM 16393

The Australian share market ended lower on Friday, dragged by the big miners, as global demand worries hit the prices of oil and base metals. The benchmark S&P/ASX200 index fell 52.3 points, or 1.37 per cent, at 3,761.6, while the broader All Ordinaries index lost 49.3 points, or 1.3 per cent, to 3,755.4. Resources stocks are expected to gain as commodities prices were firmer. The Australian Securities and Investments Commission will lift a ban on covered short-selling of financial stocks effective from the opening of trade today.

Read Full Article

Biodiem Limited ASX: BDM - 2007 Annual General Meeting Summary - Dr Andrew O'Brien, Managing Director

🕔11/30/2007 3:47:00 PM 5848

Biodiem Limited (ASX: BDM) - 2007 Annual General Meeting Summary - Dr Andrew O'Brien, Managing Director; Biodiem Limited (ASX: BDM) present the following audio webcast regarding "2007 Annual General Meeting Summary". You may also download this audio webcast to your computer or portable audio player.

Read Full Article

Biodiem Limited ASX: BDM - FY07 Results And Commencement Of 4 New Monash Studies For Eye Drug BMD-E - Mr Tom Williams, MD

🕔8/31/2007 4:05:00 PM 5382

Biodiem Limited (ASX: BDM) - FY07 Results and Commencement of 4 New Monash Studies for Eye Drug BMD-E - Mr Tom Williams, MD; Biodiem Limited (ASX: BDM) present the following audio webcast regarding "FY07 Results and Commencement of 4 New Monash Studies for Eye Drug BMD-E". You may also download this audio webcast to your computer or portable audio player.

Read Full Article

Biodiem Limited ASX: BDM - Completes Treatment Phase I And II Study Of Eye Drug - Mr Tom Williams, MD

🕔8/13/2007 4:15:00 PM 5116

Biodiem Limited (ASX: BDM) - Completes Treatment Phase I and II Study of Eye Drug - Mr Tom Williams, MD; Biodiem Limited (ASX: BDM) present the following audio webcast regarding "Completes Treatment Phase I and II Study of Eye Drug". You may also download this audio webcast to your computer or portable audio player.

Read Full Article

BioDiem To Commence Diabetic Blindness Trial with BDM-E Treatment

🕔12/2/2005 1:36:33 AM 7083

Australian biopharmaceutical development company BioDiem Ltd (ASX: BDM) announced today it has received regulatory approval to commence a phase I/II clinical trial for its peptide BDM-E in patients with diabetic macula oedema, a leading cause of blindness.

Read Full Article

BioDiem receives milestone payment of US$1m for Flu Vaccine from Nobilon

🕔11/29/2005 8:24:04 AM 6573

Australian biopharmaceutical development company BioDiem Ltd (ASX:BDM) announced today it had received payment of US$1m from Akzo Nobel's Nobilon on the anniversary of signing a licensing agreement granting Nobilon the majority of rights to BioDiem's novel intranasal influenza vaccine.

Read Full Article
###

52,302 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 19) (Last 30 Days: 87) (Since Published: 8618) 

Company Data

    Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Listed
  • 2004/01/28